Navigation Links
New report offers a primer for doctors' use of clinical genome and exome sequencing
Date:6/18/2014

Sooner than almost anyone expected, a new, genome-based technology for demystifying undiagnosed illnessesparticularly rare childhood diseasesis moving from research laboratories into general medical practice. Now, two leading scientists have sketched out what doctors need to know in order to use the new technology effectively.

"This primer illustrates how rapidly the use of genome sequencing has moved into clinical practice," said NHGRI Director Eric D. Green, M.D., Ph.D. "Its authors lay out an approach for physicians to follow when using these exciting new technologies."

Several thousand physicians already have ordered clinical genome or exome sequencing (CGES) for their patients, Leslie G. Biesecker, M.D., of the National Human Genome Research Institute and Robert C. Green, M.D., M.P.H., of Brigham and Women's Hospital and Harvard Medical School, Boston, note in the June 19, 2014, issue of the New England Journal of Medicine (NEJM). Biesecker, chief of NHGRI's Medical Genomics and Metabolic Genetics Branch, predicted that about 10,000 such tests will be ordered this year, and even more than that next year.

"The technologies that were used for the Human Genome Project are now distilled down to practical tools that clinicians can use to diagnose and, hopefully, treat diseases in patients that they couldn't treat before," Dr. Biesecker said. "It's come much faster and developed more quickly and become more useful clinically than I think any reasonable person would have suggested just 10 years ago. At that time, I don't think anybody would have taken you seriously if you had said that in 2014, tens of thousands of patients would be getting clinical genome and exome sequencing."

Exome sequencing amounts to an abridged version of the more complete, but more costly, genome sequencing. Instead of targeting 3 billion base pairs of a human's genome, exome sequencing focuses on the DNA segments, known as exons, that code for proteins. These make up 1 to 2 percent of the human genome and account for about 20,000 genes. Once a patient's DNA is extracted and the exons sequenced, computer programs identify differences between the patient's DNA and a reference sequence for the human genome. These variants may point to the cause of the patient's disease.

In an NHGRI-funded study published in the NEJM last year, exome sequencing identified the genetic cause of disease in about 25 percent of patients. The technique has identified causative or contributory gene variants in a host of diseases, including Charcot-Marie-Tooth disease, mental retardation, other neuropathies, metabolic disorders, epilepsy, cardiomyopathy, cancer and amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease).

"This is a transformative moment in the history of medicine as we begin to integrate genome sequencing into the care of patients," said Dr. Robert Green, who leads the NHGRI-funded MedSeq Project and several other translational genomics research projects at Brigham and Women's Hospital and Harvard Medical School. "While our focus in this article is on the use of sequencing in cases where diagnosis is difficult, the sequence is just the beginning. We can expect these technologies to help us transition our entire approach in medicine to more personalized and preventive care."

Whether and to what degree health insurance companies will pay for genome or exome sequencing are open questions. So far, as with other genetic tests, insurers have covered some cases, "Anecdotally, some labs are telling us that insurers are reimbursing for these," said Dr. Biesecker.

The authors agree that physicians must understand that exome sequencing can't answer all questions and isn't appropriate for all patients. The purpose of their article is to outline what physicians need to know in order to use it properly. For example:

  • While these technologies are sometimes referred to as whole-genome or whole-exome sequencing, they don't cover 100 percent of the genome or exome. Because of the way the target DNA sequences are gathered and assembled, not all of the DNA can be sequenced and the technique is best at detecting single-nucleotide variants, or alterations in sequences of no more than 8-10 base pairs. It may not pick up longer variations or repetitions of sequences, or long deletions that are responsible for some genetic disorders.

  • Patients for whom the technology is most promising are those with rare disorders that seem to be the result of variants in a single gene. Physicians should explore family historythe presence and pattern of similar disorders among relativesand should carry out an extensive literature search before ordering exome sequencing. Informed consent is essential.

  • Exome sequencing may not provide a diagnosis. On average, about 25 percent of such tests identify a gene variant that causes disease; most come up empty. Because of the technology's gaps, however, a negative result doesn't necessarily rule out a genetic cause for the disease.

  • Most of the time, identifying a genetic cause won't lead to a cure. Even in these cases, exome sequencing may still be useful because it can end an expensive, potentially invasive and stressful, diagnostic odyssey.

  • Analysis of the results may produce incidental findingsdiscovery of a gene variant that is unrelated to the patient's primary disorder but that could cause disease and require medical surveillance or treatment for a separate condition.

  • Counseling patients and their families about what to expect is essential, but challenging because the patient may be disappointed with an inconclusive outcome of such an extensive and expensive test.

In their NEJM article, the authors make clear that exome sequencing will be used across a spectrum of medical specialties and not just by geneticists. "We think that physicians from different specialties can order this test if they're willing to take the time and commit to the effort to learn what the test is, what it isn't, how it works, what it tells you and doesn't tell you, and how to use the results," Dr. Biesecker explained.

Physicians must learn which disorders are appropriate for such testing, what family histories suggest a single-gene cause, and how to interpret ambiguous results when a test points to a gene or several genes that might be responsible, Dr. Biesecker said. "If you're willing to learn those things, I think you can use the test clinically," he said. "If you're not willing to learn those things, you probably shouldn't be ordering the test, and you probably should refer the patient to somebody who is willing to learn these things."

Some experts have questioned whether genome and exome sequencing is ready for broad applicationor more precisely, whether the medical community is well enough versed in genetics to recognize the strengths and weaknesses of the testing. The authors note that, ready or not, the technology is here, physicians are ordering genome and exome sequencing for their patients and use will only increase.


'/>"/>

Contact: Raymond MacDougall
macdougallr@mail.nih.gov
301-443-3523
NIH/National Human Genome Research Institute
Source:Eurekalert

Related medicine news :

1. Young girls more likely to report side effects after HPV vaccine
2. Preteens More Likely to Report HPV Vaccine Side Effects
3. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
4. Report says new evidence could tip the balance in aspirin cancer prevention care
5. U.S. Spends Too Little on Public Health Initiatives: Report
6. NJ stroke researchers report advances in spatial neglect research at AAN Conference
7. Mental Illness Tied to Higher Rates of Physical Problems: Report
8. Diagnostic yield of colonoscopy for melena after nondiagnostic upper endoscopy is lower than previously reported
9. Report outlines successes, challenges in cancer prevention efforts
10. Healthy Lifestyle Choices Could Cut Cancer Rates: Report
11. On-the-job deaths steady in Michigan; Number of burn injuries underreported
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... From March 4 through ... Dermatology Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C. ... the condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, the company ...
(Date:2/11/2016)... Diego, CA (PRWEB) , ... February 11, 2016 , ... ... which was held in San Diego, CA, on February 6th & 7th, 2016 according ... combine for those who were not invited to the NFL’s combine in Indianapolis,” says ...
(Date:2/11/2016)... ... 11, 2016 , ... The book, “Computers Should Just Work!”, provides a basic, ... your IT consultant before signing a contract and how to spot an incompetent or ... relying heavily on e-mail and technology, it’s more important than ever to make sure ...
(Date:2/11/2016)... ... February 11, 2016 , ... As part of their 2015 end of ... Round Table Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian ... Billy Cundiff. , “We are honored to support a promising young investigator from Dr. ...
(Date:2/10/2016)... Culver City, California (PRWEB) , ... February 10, ... ... Molecular Imaging Society (WMIS), known as the World Molecular Imaging Congress (WMIC), will ... The theme for the 2016 meeting is “Imaging Biology…Improving Therapy.” The congress will ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... --> --> This press release is ... --> Japan .  --> A separate press release has ... Shire continues to strengthen its presence ... Shire continues to strengthen its presence in ... continues to strengthen its presence in ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... YORK , Feb. 10, 2016 Immune ... biopharmaceutical company, announced today that it has filed a ... Leukemia and other cancers. --> ... treating cancer by administration of Ceplene (histamine dihydrochloride) in ... provides methods of predicting the efficacy of Ceplene and ...
Breaking Medicine Technology: